[go: up one dir, main page]

MA45688A - Compositions et procédés de potentialisation d'agents antimicrobiens - Google Patents

Compositions et procédés de potentialisation d'agents antimicrobiens

Info

Publication number
MA45688A
MA45688A MA045688A MA45688A MA45688A MA 45688 A MA45688 A MA 45688A MA 045688 A MA045688 A MA 045688A MA 45688 A MA45688 A MA 45688A MA 45688 A MA45688 A MA 45688A
Authority
MA
Morocco
Prior art keywords
potentialization
compositions
methods
antimicrobial agents
antimicrobial
Prior art date
Application number
MA045688A
Other languages
English (en)
Inventor
Ephraim Brener
Elran Haber
Ascher Shmulewitz
Adi Zuloff-Shani
Original Assignee
Therapix Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapix Biosciences Ltd filed Critical Therapix Biosciences Ltd
Publication of MA45688A publication Critical patent/MA45688A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA045688A 2016-07-14 2017-07-13 Compositions et procédés de potentialisation d'agents antimicrobiens MA45688A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662362082P 2016-07-14 2016-07-14

Publications (1)

Publication Number Publication Date
MA45688A true MA45688A (fr) 2019-05-22

Family

ID=60952228

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045688A MA45688A (fr) 2016-07-14 2017-07-13 Compositions et procédés de potentialisation d'agents antimicrobiens

Country Status (9)

Country Link
US (3) US20190183914A1 (fr)
EP (1) EP3484469B1 (fr)
CN (3) CN119770661A (fr)
CA (1) CA3068806A1 (fr)
DK (1) DK3484469T3 (fr)
ES (1) ES2985112T3 (fr)
MA (1) MA45688A (fr)
PL (1) PL3484469T3 (fr)
WO (1) WO2018011813A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207414B2 (en) 2015-09-22 2021-12-28 Graphium Biosciences, Inc. Cannabinoid glycoside prodrugs and methods of synthesis
WO2018208875A1 (fr) 2017-05-09 2018-11-15 Vitality Biopharma, Inc. Compositions antimicrobiennes comprenant des cannabinoïdes et leurs méthodes d'utilisation
US12198788B2 (en) * 2017-10-04 2025-01-14 Cannibite Bvba System for detecting an intraoral disease and determining a personalized treatment scheme and method of doing same
WO2020000024A1 (fr) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Traitement antibactérien utilisant des combinaisons de cannabinoïdes
US20210315837A1 (en) * 2018-09-05 2021-10-14 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
EP3873449A1 (fr) * 2018-10-30 2021-09-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions comprenant des cannabinoïdes destinées à être utilisées dans le traitement d'un biofilm et d'états associés à des infections microbiennes, fongiques, bactériennes
GB2581987B (en) * 2019-03-06 2021-11-17 Gw Res Ltd Use of cannabidiol in combination with antibiotics
EP3946315A4 (fr) * 2019-03-28 2023-04-12 Scicann Therapeutics Inc. Compositions de cannabinoïdes et leur utilisation
CN109758441A (zh) * 2019-03-29 2019-05-17 广东工业大学 N-脂肪酰基乙醇胺类化合物在制备抑制细菌群体感应系统的药物中的应用和药物
CN113710263A (zh) 2019-05-06 2021-11-26 大不列颠哥伦比亚大学 抗生大麻素-萜烯制剂
AU2020297660A1 (en) * 2019-06-18 2021-12-09 Botanix Pharmaceuticals Limited Antibacterial dosage regime using cannabinoids
EP3986882A4 (fr) 2019-06-24 2023-04-05 Diverse Biotech, Inc. Molécules conjuguées de bêta-lactame-cannabinoïde
CN110973159B (zh) * 2019-10-30 2021-04-06 广州市浪奇实业股份有限公司 一种含有大麻二酚的抗菌组合物及其应用
US20230013669A1 (en) * 2019-11-29 2023-01-19 Botanix Pharmaceuticals Limited Antibacterial Treatment Using a Cannabinoid and an Active Agent
CN112195558A (zh) * 2020-09-24 2021-01-08 上海丰格无纺布有限公司 一种抗微生物无纺布及其制备方法
WO2023130142A2 (fr) * 2022-01-03 2023-07-06 Bryant Cynthia W Compositions et procédés utilisant des composés cannabinoïdes pour traiter des troubles des voies urinaires
WO2024159198A2 (fr) * 2023-01-27 2024-08-02 Nagy Aurangzeb Nafees Compositions et procédés utilisant du tétrahydrocannabinol et compositions le comprenant pour traiter des indications impliquant une inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506224A (en) 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
US6348498B1 (en) 1998-05-29 2002-02-19 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
US20050054730A1 (en) 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
WO2009158499A2 (fr) * 2008-06-25 2009-12-30 University Of North Texas Health Science Center At Fort Worth Prévention de la croissance bactérienne et de la formation de biofilm par des ligands qui agissent sur les systèmes cannabinoïdergiques
WO2010013240A1 (fr) 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions et procédés de traitement de troubles inflammatoires
CN103361820A (zh) * 2012-03-30 2013-10-23 太仓棨淂服装有限公司 一种抗菌牛仔面料
WO2015048508A1 (fr) * 2013-09-26 2015-04-02 Sekura Ronald D Traitements topiques comprenant un produit médicamenteux botanique dérivé du cannabis sp.

Also Published As

Publication number Publication date
ES2985112T3 (es) 2024-11-04
CN119770661A (zh) 2025-04-08
EP3484469A4 (fr) 2020-07-22
US20210093652A1 (en) 2021-04-01
DK3484469T3 (da) 2024-06-24
CN109562094A (zh) 2019-04-02
US20190183914A1 (en) 2019-06-20
PL3484469T3 (pl) 2024-08-19
CN119633002A (zh) 2025-03-18
US11491172B2 (en) 2022-11-08
EP3484469B1 (fr) 2024-05-22
US20230045747A1 (en) 2023-02-09
WO2018011813A1 (fr) 2018-01-18
CA3068806A1 (fr) 2018-01-18
EP3484469A1 (fr) 2019-05-22

Similar Documents

Publication Publication Date Title
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA45290A (fr) Procédés et compositions d'agents biologiquement actifs
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
EP3273944A4 (fr) Compositions et procédés permettant d'administrer des agents de type biomacromolécule
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
EP3325017A4 (fr) Compositions d'oligonucléotides et procédés associés
MA42269A (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
EP3474857A4 (fr) Compositions et méthodes de libération d'agents thérapeutiques
EP3512351A4 (fr) Compositions et procédés d'amélioration de goût d'édulcorants non nutritifs
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3349743A4 (fr) Procédés et compositions d'inhibition de l'interaction dcn1-ubc12
EP3250367A4 (fr) Étalonnage d'agent
EP3496768A4 (fr) Compositions antimicrobiennes et procédés d'utilisation associés.
EP3289064A4 (fr) Compositions et procédés pour la détection d'allergènes
EP3310376A4 (fr) Agents thérapeutiques modifiés et compositions associées
EP3412344A4 (fr) Composition d'agent extincteur
EP3389673A4 (fr) Procédés et compositions pour l'administration de polynucléotides
EP3380471A4 (fr) Méthodes et compositions d'inhibition de comt
EP3426349A4 (fr) Procédés et compositions pour inhiber l'expression de pmp22
EP3530722A4 (fr) Composition d'agent nettoyant
EP3402443A4 (fr) Dispositifs et compositions et leurs procédés d'utilisation
EP3491329A4 (fr) Propergol et compositions d'auto-protection
IL264445A (en) Compounds and compositions and uses thereof